Takeda appoints Hernán Porcile as Head of the EAMEA region
Takeda has appointed Hernán Porcile as the new Area Head for its…
Takeda and the Saudi Gastroenterology Association strengthen partnership to advance IBD care in Saudi Arabia
Takeda announced the signing of a new Memorandum of Understanding (MoU) with…
Takeda Hosts IBD Nexus Summit 2025 to Advance Patient Care
Dubai, UAE- February 2025: Takeda hosted the IBD Nexus Summit 2025 at…
Takeda hosts regional event to advance hereditary angioedema care in the Middle East
Dubai, UAE- December 2024- Global biopharmaceutical company Takeda recently hosted the event…
Takeda hosted inflammatory bowel disease “IBD Aware” forum in Riyadh
Riyadh, The Kingdom of Saudi Arabia, November 28, 2024: Global biopharmaceutical company…
DoH and Takeda Pharmaceuticals Ink Strategic Partnership
June 2024- The Department of Health – Abu Dhabi (DoH) signed a…
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 in cTTP
May 31, 2024- Takeda announced that the European Medicines Agency’s (EMA) Committee…
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab)
Osaka, Japan- April 2024- Takeda announced that the U.S. Food and Drug…
Takeda’s Global Initiative Brings IBD Challenges to the Forefront in the UAE
Dubai, UAE- March 2024- Takeda, the patient-centric biopharmaceutical company, brought its global…